Friday, August 29th, 2025
Stock Profile: OTLK
OTLK Logo

Outlook Therapeutics, Inc. (OTLK)

Market: NASD | Currency: USD

Address: Building F

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, Show more




📈 Outlook Therapeutics, Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2024 - $0.050000 - 2024-03-14 - Stock split
Total Amount for 2024: $0.050000
2019 - $0.125000 - 2019-03-18 - Stock split
Total Amount for 2019: $0.125000


📅 Earnings & EPS History for Outlook Therapeutics, Inc.


DateReported EPS
2025-12-26 (estimated upcoming)-
2025-08-14-0.44
2025-05-15-0.34
2025-02-14-0.89
2024-12-27-0.94
2024-08-14-0.83
2024-05-15-1.55
2024-02-14-0.78
2023-12-22-0.94
2023-08-14-1.38
2023-05-15-0.52
2023-02-14-1.59
2022-12-29-1.29
2022-08-10-1.56
2022-05-13-1.77
2022-02-14-1.41
2021-12-22-1.6
2021-08-13-1.4
2021-05-14-1.8
2021-02-16-2.2
2020-12-23-0.51
2020-08-14-2.2
2020-05-15-2.6
2020-02-14-5.6
2019-12-191.06




📰 Related News & Research


No related articles found for "outlook therapeutics".